central retinal vein

Also found in: Acronyms, Wikipedia.

cen·tral retinal vein

the vein, formed by union of the retinal veins; accompanies the artery of the same name in the optic nerve.
Synonym(s): vena centralis retinae [TA]
Farlex Partner Medical Dictionary © Farlex 2012

Central retinal vein

Central blood vessel and its branches that drains the retina.
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Thrombophilic risk factors in patients with central retinal vein occlusion.
Conclusion: Radial optic neurotomy improved both the visual function and macular edema in ischemic central retinal vein occlusion.
Central Retinal Artery Equivalent and Central Retinal Vein Equivalent were explored to meet the challenge raised in the study of retinal vascular dimension when retinal microvascular anatomy has been found different in different individuals [72].
Ho et al., "Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology," Ophthalmology, vol.
Late hyperbaric oxygen treatment of cilioretinal artery occlusion with nonischemic central retinal vein occlusion secondary to high altitude.
Azad, "Case report: bilateral simultaneous central retinal vein occlusion in Waldenstroom's macroglobulinemia," Optometry, vol.
CRVO is caused by a circulatory disturbance at the trunk of the central retinal vein near the lamina cribrosa.
* Central retinal vein occlusion (CRVO) has various etiologies, mostly because of hypercoagulopathies or cardiovascular diseases.
Specifically designed for the eye and proven to save sight, ranibizumab is indicated for the treatment of neovascular wet age-related macular degeneration (wet AMD), visual impairment due to DME and due to macular edema secondary to both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO); and visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).
Outside the U.S., Lucentis is approved in more than 100 countries to treat patients with wet AMD, for the treatment of DME, and due to macular edema secondary to both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

Full browser ?